CytomX Therapeutics (6C1) Price & Analysis

3 Followers

6C1 Stock Chart & Stats

€4.25

-€0.17(-15.59%)

At close: Jan 08 4:00 PM EST

€4.25

-€0.17(-15.59%)

Day’s Range― - ―

52-Week Range€1.47 - €6.97

Previous CloseN/A

Volume1.63K

Average Volume (3M)470.00

Market Cap

€704.44M

Enterprise Value€450.07M

Total Cash (Recent Filing)€346.71M

Total Debt (Recent Filing)€2.86M

Price to Earnings (P/E)―

Beta1.37

Next Earnings

Aug 06, 2026

EPS Estimate

-0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.36

Shares Outstanding217,702,910

10 Day Avg. Volume348

30 Day Avg. Volume470

Financial Highlights & Ratios

PEG Ratio0.20

Price to Book (P/B)5.93

Price to Sales (P/S)7.71

P/FCF Ratio-7.75

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€10.39

Price Target Upside144.46% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-0.37

Revenue Forecast (FY)€26.56M

Bulls Say, Bears Say

Bulls Say

Strategic Partnership ExpansionThe expanded Regeneron collaboration materially increases program scope and potential milestone/royalty upside, giving CytomX validated commercial optionality and a long-duration partner funding stream that can underwrite R&D and de‑risk advancement of Probody-enabled assets.

Strengthened Cash RunwayA >$340M cash position and runway into H2 2028 meaningfully reduce near-term financing pressure, enabling prioritized investment in Varseta‑M and planned registrational activities while preserving strategic flexibility to fund combination and expansion trials without immediate dilution.

Promising Varseta‑M Clinical EfficacyObserved ORR and PFS materially exceed typical late‑line CRC benchmarks, suggesting a differentiated therapeutic profile. Durable efficacy increases probability of a viable registrational pathway, supports combination and label expansion strategies, and strengthens long‑term commercial prospects if safety holds.

Bears Say

Revenue Volatility And Cash BurnRevenue is highly variable due to milestone timing; combined with ~-$80M operating/FCF burn, this creates persistent financing reliance. Over the medium term, the company must convert clinical progress into stable milestone receipts or control burn to avoid recurring equity raises that dilute shareholders.

Clinical Tolerability RiskGrade‑3 diarrhea at the optimization doses poses a durable regulatory and dosing tradeoff: if tolerability cannot be consistently managed, dose selection may be compromised, limiting efficacy or complicating approval, label restrictions, and commercial uptake even if efficacy signals persist.

Dilution/Capital Structure RiskBroad approval to expand share authorization and equity reserves improves financing flexibility but raises the structural risk of dilution. If development milestones or further trials require capital, the company is positioned to issue equity, which can dilute existing holders and influence long‑term per‑share economics.

CytomX Therapeutics News

Citizens healthcare analysts hold an analyst/industry conference call

Healthcare Analysts discuss understanding the developing landscape in Colorectal Cancer (CRC) (relevant companies BCAX, CTMX, EXEL, INBX, INCY,...

8d ago

CTMX

EXEL

CytomX Shareholders Approve Expanded Equity and Capital Plans

CytomX Therapeutics ( ($CTMX) ) just unveiled an update. CytomX Therapeutics’ stockholders approved several significant capital and compensation...

23d ago

CTMX

3 Best Cheap Stocks Under $10 to Buy Now, According to Analysts

Low‑priced stocks do not mean low potential. Several stocks under $10 are drawing attention from Wall Street analysts...

1M ago

CWH

CytomX Expands High-Value Bispecific Cancer Partnership With Regeneron

The latest announcement is out from CytomX Therapeutics ( ($CTMX) ). On May 29, 2026, CytomX Therapeutics and...

1M ago

CTMX

CytomX Therapeutics expands licensing agreement with Regeneron

CytomX Therapeutics (CTMX) announced an expansion of its collaboration and licensing agreement with Regeneron Pharmaceuticals (REGN) to create...

1M ago

CTMX

REGN

5 Healthcare Stocks Set to Join the Russell 3000

FTSE Russell has released its preliminary changes for the Russell 3000 Index ahead of the official rebalancing on...

2M ago

QSI

AGEN

CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($CTXR) ), ( ($AMT) ), ( ($JAZZ) ), ( ($CTMX)...

2M ago

AMT

CTMX

CytomX Earnings Call: Varseta‑M Drives Long Runway

CytomX Therapeutics Inc. (($CTMX)) has held its Q1 earnings call. Read on for the main highlights of the...

2M ago

CTMX

CytomX Therapeutics initiated with an Outperform at Wolfe Research

Wolfe Research initiated coverage of CytomX Therapeutics (CTMX) with an Outperform rating and $6 price target The company...

2M ago

CTMX

CytomX’s CX-801 Enters Key Early Cancer Trial Phase, Putting CTMX Back on Investor Radar

CytomX Therapeutics Inc. ($CTMX) announced an update on their ongoing clinical study. The first in human study CTMX-801-101,...

2M ago

CTMX

CytomX Therapeutics price target lowered to $11 from $17 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on CytomX Therapeutics (CTMX) to $11 from $17 and keeps a...

2M ago

CTMX

CytomX Therapeutics: Early-Stage Pipeline, Trial Setbacks and High Risks on the Road to Profitability

CytomX Therapeutics Inc. (CTMX) has disclosed a new risk, in the Innovation / R&D category. CytomX Therapeutics Inc....

2M ago

CTMX

CytomX Earnings Call Highlights Varseta-M Momentum

CytomX Therapeutics Inc. (($CTMX)) has held its Q1 earnings call. Read on for the main highlights of the...

2M ago

CTMX

CytomX Therapeutics reports Q1 EPS (10c), consensus (11c)

Reports Q1 revenue $10.26M, consensus $4.68M. “CytomX has continued to gain tremendous momentum in 2026 and we remain...

2M ago

CTMX

6C1 FAQ

What was CytomX Therapeutics Inc.’s price range in the past 12 months?

CytomX Therapeutics Inc. lowest stock price was €1.47 and its highest was €6.97 in the past 12 months.

What is CytomX Therapeutics Inc.’s market cap?

CytomX Therapeutics Inc.’s market cap is €704.44M.

When is CytomX Therapeutics Inc.’s upcoming earnings report date?

CytomX Therapeutics Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 22 days.

How were CytomX Therapeutics Inc.’s earnings last quarter?

CytomX Therapeutics Inc. released its earnings results on May 07, 2026. The company reported -€0.087 earnings per share for the quarter, beating the consensus estimate of -€0.106 by €0.018.

Is CytomX Therapeutics Inc. overvalued?

According to Wall Street analysts CytomX Therapeutics Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CytomX Therapeutics Inc. pay dividends?

CytomX Therapeutics Inc. does not currently pay dividends.

What is CytomX Therapeutics Inc.’s EPS estimate?

CytomX Therapeutics Inc.’s EPS estimate is -0.07.

How many shares outstanding does CytomX Therapeutics Inc. have?

CytomX Therapeutics Inc. has 217,702,910 shares outstanding.

What happened to CytomX Therapeutics Inc.’s price movement after its last earnings report?

CytomX Therapeutics Inc. reported an EPS of -€0.087 in its last earnings report, beating expectations of -€0.106. Following the earnings report the stock price went down -2.475%.

Which hedge fund is a major shareholder of CytomX Therapeutics Inc.?

Currently, no hedge funds are holding shares in DE:6C1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

CytomX Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-36.61%

Trailing 12-Months

Asset Growth

264.84%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CytomX Therapeutics Inc.

CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.

CytomX Therapeutics (6C1) Earnings & Revenues

Historic Earnings Reports

6C1 Stock 12 Month Forecast

Average Price Target

€10.39

▲(144.46% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","15":"€15","3.75":"€3.75","7.5":"€7.5","11.25":"€11.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14.04768128,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€14.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.389430946666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€10.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.2678804800000005,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€5.27</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.75,7.5,11.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.23,4.062129329230769,4.894258658461538,5.726387987692307,6.558517316923076,7.390646646153845,8.222775975384616,9.054905304615385,9.887034633846154,10.719163963076923,11.551293292307692,12.383422621538461,13.215551950769232,{"y":14.04768128,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.23,3.7807254574358975,4.331450914871795,4.882176372307692,5.432901829743589,5.983627287179486,6.534352744615384,7.085078202051282,7.635803659487179,8.186529116923076,8.737254574358973,9.28798003179487,9.838705489230767,{"y":10.389430946666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.23,3.386760036923077,3.543520073846154,3.700280110769231,3.8570401476923077,4.013800184615385,4.170560221538462,4.327320258461539,4.484080295384616,4.640840332307693,4.79760036923077,4.954360406153847,5.111120443076924,{"y":5.2678804800000005,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.864,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.872,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.707,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.66,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.898,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.604,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.498,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.564,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.468,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.158,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.414,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.021,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.23,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >